Background: Cochlear is an ASX-listed medtech company known for its world-leading hearing implants. More than 750,000 devices are sold across 180+ countries. It originally spun out of CSIRO and listed in 1995... growing from a sub-$200 million company into a $17 billion giant at its peak.

What happened: Unfortunately, that growth story has hit a speed bump. Cochlear downgraded its FY26 profit guidance (pretty majorly). We’re talking new profit expectations of between $290 million - $330 million
instead of $435 - $460 million. That's a potential 37% drop. Investors reacted fast, sending the share price down 36% - its lowest level since 2016.  

What else: The reason for the dro? A combination of hospital capacity constraints, weaker patient referrals, and softer consumer sentiment. But the key issue is that despite the medical benefits of Cochlear implants, they're still being treated as a discretionary purchase... meaning patients are delaying decisions as economic pressure builds.  

What's the key learning?

💡 When money gets tight, "nice-to-haves" don't necessarily disappear - they just get postponed. Consumers prioritise essential spending like housing, food, utilities, and basic healthcare. Discretionary spending, like travel, luxury goods, or elective medical procedures, are often delayed... even if they deliver clear benefits.    

💡 Perception matters as much as product. Even though Cochlear implants improve quality of life, they're often viewed as deferrable. That means when consumer confidence drops, demand follows. It highlights how important it is for companies to position their products as essential rather than optional.

💡 That's why Cochlear is trying to reframe its hearing implants to unlock demand. We've seen this before from drugs like Wegovy and Zepbound being repositioned from weight loss aids to treatments for chronic disease. The World Health Organization then backed their use for obesity - shifting them from "nice-to-have" to "need-to-have"... and the demand followed.